- Roche cans one Carmot obesity asset as another shows best-in-class potentialAcmopatide met the main goal of a Phase 2 study in type 1 diabetes, but Roche is axing the investigational drug to prioritize enicepatide for weight loss, type 2 diabetes and cardiovascular outcome…BioSpace · 3d ago↗ source
- Michael Ehlers joins Formation Bio to lead R&D; Black Diamond co-founder dies at 67Michael Ehlers left his CEO role at Ascidian Therapeutics, the exon editing company he co-founded, to run R&D at the AI biotech Formation Bio. It’s not often that biotech executives leave ...Endpoints · 3d ago↗ source
- STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pillMerck is striking licensing deals for its experimental HIV prevention pill in hope of getting wide-scale production started quickly.